Considering these findings together, we conclude that regional metabolic heterogeneity in GBM results in low GLS2 expression in the malignant area with low NADPH and GSH levels (high ROS) and high GLS2 expression in the lower grade area with high NADPH and GSH levels (low ROS). Here, GLS2 is linked to glioblastoma.